A multi-center, multi-national, randomized, placebo-controlled, parallel group, double-blind, Phase III trial to evaluate the efficacy and safety of LC15-0444 in patients with type 2 diabetes.

Trial Profile

A multi-center, multi-national, randomized, placebo-controlled, parallel group, double-blind, Phase III trial to evaluate the efficacy and safety of LC15-0444 in patients with type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Gemigliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 01 Oct 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
    • 17 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top